Capricor reports positive top-line results from Phase I/II trial of CAP-1002 for DMD
US-based biotechnology firm Capricor Therapeutics has reported positive top-line six-month results from the Phase I/II HOPE clinical trial of CAP-1002 to treat duchenne muscular dystrophy (DMD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Clinical Trials | Muscular Dystrophy | Pharmaceuticals | Reflex Sympathetic Dystrophy